404 related articles for article (PubMed ID: 10820356)
21. Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma.
Rao J; Seligson D; Visapaa H; Horvath S; Eeva M; Michel K; Pantuck A; Belldegrun A; Palotie A
Cancer; 2002 Sep; 95(6):1247-57. PubMed ID: 12216092
[TBL] [Abstract][Full Text] [Related]
22. Percutaneous management of renal pelvic urothelial tumors: long-term followup.
Goel MC; Mahendra V; Roberts JG
J Urol; 2003 Mar; 169(3):925-9; discussion 929-30. PubMed ID: 12576814
[TBL] [Abstract][Full Text] [Related]
23. Cyclical change of hMSH2 protein expression in normal endometrium during the menstrual cycle and its overexpression in endometrial hyperplasia and sporadic endometrial carcinoma.
Hamid AA; Mandai M; Konishi I; Nanbu K; Tsuruta Y; Kusakari T; Kariya M; Kita M; Fujii S
Cancer; 2002 Feb; 94(4):997-1005. PubMed ID: 11920468
[TBL] [Abstract][Full Text] [Related]
24. Expression of hMSH2 gene and mutant p53 in sporadic digestive tract tumors.
Kang Y; Zhang Z; Wang J; Chen J; Peng B; Kang P
Chin Med J (Engl); 2003 Jan; 116(1):53-6. PubMed ID: 12667388
[TBL] [Abstract][Full Text] [Related]
25. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases.
Guo CC; Fine SW; Epstein JI
Am J Surg Pathol; 2006 Jul; 30(7):883-91. PubMed ID: 16819332
[TBL] [Abstract][Full Text] [Related]
26. Altered expression of hMSH2 in sporadic colorectal cancer, surrounding mucosa and at distant colonic mucosa.
Giarnieri E; Consorti F; Lorenzotti A; Luzzatto L; Soda G; Bosco D; Vecchione A; Midiri G
Anticancer Res; 2000; 20(5C):3829-31. PubMed ID: 11268462
[TBL] [Abstract][Full Text] [Related]
27. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.
Alsheikh A; Mohamedali Z; Jones E; Masterson J; Gilks CB
Mod Pathol; 2001 Apr; 14(4):267-72. PubMed ID: 11301341
[TBL] [Abstract][Full Text] [Related]
29. Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis.
Lopez-Beltran A; Amin MB; Oliveira PS; Montironi R; Algaba F; McKenney JK; de Torres I; Mazerolles C; Wang M; Cheng L
Am J Surg Pathol; 2010 Mar; 34(3):371-6. PubMed ID: 20139762
[TBL] [Abstract][Full Text] [Related]
30. Comparison of multidrug resistance gene expression levels with malignant potentials and influence of chemotherapy in urothelial cancers.
Kakehi Y; Wu WJ; Kim WJ; Arao S; Fukumoto M; Yoshida O
Int J Urol; 1995 Nov; 2(5):309-15. PubMed ID: 8749949
[TBL] [Abstract][Full Text] [Related]
31. hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer.
Ercoli A; Ferrandina G; Raspaglio G; Marone M; Maggiano N; Del Mastro P; Benedetti Panici P; Mancuso S; Scambia G
Br J Cancer; 1999 Jul; 80(10):1665-71. PubMed ID: 10408416
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of plasminogen activator inhibitor type 1 expression in bladder cancer.
Becker M; Szarvas T; Wittschier M; vom Dorp F; Tötsch M; Schmid KW; Rübben H; Ergün S
Cancer; 2010 Oct; 116(19):4502-12. PubMed ID: 20564745
[TBL] [Abstract][Full Text] [Related]
33. Absent CD44v6 expression is an independent predictor of poor urothelial bladder cancer outcome.
Klatte T; Seligson DB; Rao JY; Yu H; de Martino M; Garraway I; Wong SG; Belldegrun AS; Pantuck AJ
J Urol; 2010 Jun; 183(6):2403-8. PubMed ID: 20403620
[TBL] [Abstract][Full Text] [Related]
34. Mismatch repair protein hMSH2 in primary drug resistance in in vitro human malignant gliomas.
Rellecke P; Kuchelmeister K; Schachenmayr W; Schlegel J
J Neurosurg; 2004 Oct; 101(4):653-8. PubMed ID: 15481721
[TBL] [Abstract][Full Text] [Related]
35. Urothelial neoplasms of the urinary bladder occurring in young adult and pediatric patients: a comprehensive review of literature with implications for patient management.
Paner GP; Zehnder P; Amin AM; Husain AN; Desai MM
Adv Anat Pathol; 2011 Jan; 18(1):79-89. PubMed ID: 21169741
[TBL] [Abstract][Full Text] [Related]
36. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence.
Velasco A; Hewitt SM; Albert PS; Hossein M; Rosenberg H; Martinez C; Sagalowsky AI; McConnell JD; Marston W; Leach FS
Cancer; 2002 Feb; 94(3):690-9. PubMed ID: 11857301
[TBL] [Abstract][Full Text] [Related]
37. Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile.
Dip N; Reis ST; Timoszczuk LS; Viana NI; Piantino CB; Morais DR; Moura CM; Abe DK; Silva IA; Srougi M; Dall'Oglio MF; Leite KR
J Urol; 2012 Nov; 188(5):1951-6. PubMed ID: 22999546
[TBL] [Abstract][Full Text] [Related]
38. Chromosomal imbalances in successive moments of human bladder urothelial carcinoma.
Nascimento e Pontes MG; da Silveira SM; Trindade Filho JC; Rogatto SR; Viana de Camargo JL
Urol Oncol; 2013 Aug; 31(6):827-35. PubMed ID: 21763161
[TBL] [Abstract][Full Text] [Related]
39. Missense mutation of the hMSH6 and p53 genes in sporadic urothelial transitional cell carcinoma.
Furihata M; Shuin T; Takeuchi T; Sonobe H; Ohtsuki Y; Akiyama Y; Yuasa Y
Int J Oncol; 2000 Mar; 16(3):491-6. PubMed ID: 10675480
[TBL] [Abstract][Full Text] [Related]
40. Expression of human MutS homolog 2 (hMSH2) protein in resting and proliferating cells.
Marra G; Chang CL; Laghi LA; Chauhan DP; Young D; Boland CR
Oncogene; 1996 Nov; 13(10):2189-96. PubMed ID: 8950986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
